MS drug, Mayzent, receives FDA approval
by Press Release from Outbreak News Today on (#4BX4H)
The U.S. Food and Drug Administration today approved Mayzent (siponimod) tablets to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. "Multiple sclerosis can have a profound impact on a person's life," said Billy Dunn, M.D., director of the Division of Neurology Products ["]
The post MS drug, Mayzent, receives FDA approval appeared first on Outbreak News Today.